Alkem launches Pertuza, a pertuzumabbiosimilar, in India for treatment of HER2-positive breast cancer
Alkem aims to expand access to treatment with its affordable pertuzumab biosimilar that meets global standards and is backed by trusted scienceMumbai, September 22, 2025: Alkem Laboratories Ltd. (BSE: 539523, NSE:…